Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 28, 2022CancersOpen Access

Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJin Sun LeeSYSusan E. YostSLSierra Min Li

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lee et al. (2022) studied this question.

synapsesocial.com/papers/6a11d41a37ecc83ca3fd4eb5https://doi.org/10.3390/cancers14133159
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer2016 · 2,066 citations
  2. 2Comprehensive molecular portraits of human breast tumours2012 · 12,630 citations
  3. 3FOXA1 Directs H3K4 Monomethylation at Enhancers via Recruitment of the Methyltransferase MLL32016 · 174 citations
  4. 4Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)2020 · 1,034 citations
  5. 5Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer2021 · 49 citations